The investigation that led to MYODM

According to data gathered by Myogem Health Company from experiments  in vitro and in vivo over a period of 10 years, MYODM has proven its ability to increase the levels of “expression de” MBNL, both MBNL1 and MBNL2  and the effective amount in the nucleus of the human myoblasts MD1.   

Muscleblind type proteins (MBNL) are key regulators in the mARN metabolism in mammals. MBNL is involved in 80% of  regulating mechanisms in the multisystem effects of MD1. Therefore an increase in MBNL could mean an improvement in at least 80% of the multisystem effects of the disorder

MBNL 1 is the most investigated member of the MBNL protein family due to its predominant exposition in muscle tissue, as in brain, heart and liver. It is also an important regulator of  the alternative processing of “transcritos”. Hundreds of alternative exons have their processing altered in DM1 and some of them directly correlate with the symptoms of MD1. In fact the functional diminution of MNBL1 is the key element in the pathogenesis of MD1. It was found that the lack of MBNL function in humans leads to a defect on the transfer of fetal splicing patterns to the adult pattern in all the “transcritos” regulated by MBNL. The combination of caffeine and theobromine in the proportions present in MYODM had a synergistic effect on the increase of MBNL in the transcription and level of the protein, after being administered to myoblasts of human DM1

When administered to DM1 animals MYODM increased their survival rate, improved the muscle zone, cardiac malfunction and locomotive malfunction and reduced both redox and autophagy levels in these laboratory animals Therefore MYODM has the capacity to rescue in vivo the phenotypes related to MD1  and generally improve the quality of life of MD1 individuals administered  this product.


The main ingredients of  MYODM are the  methylxanthines theobromine and caffeine, made up of an optimum composition and dosis obtained after investigation and development of the product. Methyxanthines are secondary metabolites from plants derived from purina nucleosides and can be found in almost 100 different species (including Theobromine cacao, Coffea Arabica and  Camelia Sinensis) No other foodstuff contains the proportion of theobromine and caffeine formulated in MYODM


MYODM contains 20mg of caffeine per capsule. The daily dosis of 3 capsules at 8 hour intervals implies a maximum daily intake of 60mg.

MYODM complies with current legislation regarding caffeine intake in complementos alimenticios for those who accept a maximum daily  intake of 80mg.

The intake of 1 capsule of MYODM (with 20mg caffeine) is an ingestion of 0.28mg/kg in an individual weighing 70kg

The European Food Safety Authority (EFSA) in its reports submitted by experts (“Scientific Opinion on the safety of caffeine”, EFSA Journal 2015;13(5):4102) indicates that, in the overall healthy general public, a dosis of up to 3mg/kg for an adult weighing 70kg is safe (equal to 200mg of caffeine in 1 dosis). In general a daily dosis of 400mg of caffeine in adults is considered to be safe. Therefore The EFSA states that a dosis of caffeine 10 times more than that present in 1 capsule of MYODM is safe